Why senescent cells sabotage cardiac recovery after a heart attack

Senescent cells play a deceptively dual role in cardiac recovery: they initially orchestrate tissue repair through immune and regenerative signaling, yet when they persist beyond their therapeutic window—particularly following severe infarction—they become silent saboteurs of cardiac function. The mechanism centers on the senescence-associated secretory phenotype (SASP), a pattern of persistent inflammation that unfolds across three distinct phases: acutely amplifying necessary immune recruitment, subacutely facilitating repair and scar formation, then chronically perpetuating pathological fibrosis and ventricular dysfunction. This sustained SASP expression emerges as the primary driver of adverse ventricular remodeling and excessive fibrosis that leads to heart failure. The spatiotemporal heterogeneity of these signals—operating simultaneously in the infarct zone, the border region, and distal myocardium—explains why pharmacological intervention demands surgical timing precision. For the longevity-focused reader, this opens a strategic window: senolytic therapies precisely targeting these senescent cells immediately following ischemic injury could fundamentally reshape clinical outcomes, converting myocardial infarction from inevitable sudden death into reparable injury.